Inhibition of LILRB signaling may also synergize with anti–PD-1/PD-L1 therapies, tumor vaccines, or cytokine-based treatments to overcome immune resistance and broaden the efficacy of immunotherapy (157, 161, 163–165). The gene discussed is CD274; the disease is neoplasm.